Psychedelic neuroscientist Manesh Girn talks about his research into neuroimaging of the brain while subjected to psychedelic states and more.
Similar Posts
Adapting a Functional Mushroom Routine with Jack Savage
In this episode, Dennis Walker sits down with Jack Savage to discuss the business model behind Everyday Dose.
Industry NEWS: The GOOD, The BAD, And The UGLY / New Psychedelic Studies, Legalization Bills & MORE!
Hey guys! In this week’s general industry news, we’ll cover some interesting developments. Some are probably going to make some of our viewers turn away from this week’s episode as they discover some pretty “depressing” statistics about North America’s current mental state. However, for those who stick around, you might end up finding that there might be a light at the end of the tunnel as you discover that psilocybin’s benefits might be extended to treat certain
Enjoy!
Links:
Psilocybin & Migraines: https://www.psypost.org/2021/05/a-single-dose-of-psilocybin-has-a-lasting-therapeutic-effect-on-migraine-headache-according-to-a-new-placebo-controlled-study-60793
Increased depression in North America:
https://www.meetfieldtrip.com/news/news-details/2021/Canadians-Are-Not-OK-83-of-Canadians-Report-One-Or-More-Symptoms-of-Depression-With-Many-Turning-To-Substances-To-Cope-With-Negative-Emotions-During-COVID-19-Pandemic-According-to-Field-Trip-Healths-First-Annual-State-of-Mind-Survey/default.aspx
https://www.meetfieldtrip.com/news/news-details/2021/More-than-80-of-Americans-report-one-or-more-symptoms-of-depression-and-many-have-turned-to-substances-to-cope-with-negative-emotions-during-COVID-19-Pandemic-according-to-Field-Trip-Healths-First-Annual-State-of-Mind-Survey/default.aspx
Opioid Overdose In Ontario:
https://www.cp24.com/news/opioid-overdose-deaths-up-75-per-cent-in-ontario-during-covid-19-pandemic-new-report-1.5434080
FDA Greenlights Ketamine:
https://psychedelicspotlight.com/ketamine-study-parkinsons-disease-treatment/
California Bill to Decriminalize Psychedelics Passes Senate Floor:
https://www.marijuanamoment.net/california-bill-to-legalize-possession-of-psychedelics-heads-to-senate-floor-after-committee-action/
Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!
Follow us on social media! 🙌
Instagram: @thepsychedelicinvestor
Email: thepsychedelicinvestor@gmail.com
Facebook: @thepsychedelicinvestor
Music: www.bensound.com
Video editing: @themyaholy
https://benzinga.grsm.io/jameshallifax1834
https://benzinga.grsm.io/thepsychedelicinvestor
DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.
#MindMed #PsychedelicStocks #PsychedelicIndustry
Interview With Henri Sant-Cassia
In today’s episode of the Psychedelic Spotlight podcast, we spotlight Henri Sant-Cassia, Co-Founding Partner of The Conscious Fund, a leading investment fund in the medicinal psychedelics industry, focused on early stage ventures and psychedelic medicine that are helping to deliver better outcomes for mental health, addiction and pain.
Interview With Jemie Sae Koo
In this episode of the Psychedelic Spotlight podcast, we feature Jemie Sae Koo, CEO and Founder of Psychable.
HAVN Life Sciences Update
HAVN Life Sciences Inc. CEO, Tim Moore, updates the recent…
Can TRYP Therapeutics Treat Chronic Pain and Eating Disorders With Psychedelics? (TRYP / TRYF)
In today’s episode, we’ll be interviewing CEO and Chairman of TRYP Therapeutics, Greg Mckee. Thus far, this is one of the most informative conversations I’ve had the pleasure of having about the psychedelic industry, the different segments that could be simultaneously tackled, the challenges and opportunities for many of the players in this industry and much more.
I hope you stay till the end and are able to get some value from this discussion.
TRYP Therapeutics (CSE: TRYP) (OTC: TRYPF), is a pharmaceutical company focused on identifying and developing clinical-stage compounds for orphan diseases and other diseases with high unmet medical needs. Some of the diseases TRYP is addressing are: eating disorders and fibromyalgia (chronic widespread pain) .
TRYP intends to seek approval from FDA to proceed directly into a Phase 2 clinical trial based on existing preclinical and clinical data for the active pharmaceutical ingredients in TRP-8802 and TRP-8803.
Timestamps:
0:00 – Intro
0:40 – TRYP’s mission and Greg Mckee’s personal involvement
2:59 – Expanding on TRYP’s main molecules: TRP 8802 and TRP 8803
8:18 – Expanding on TRYP’s flagship programs: Fibromyalgia and Eating Disorder
14:29 – Clinical trial progress and anticipated start of Phase IIa trials
18:26 – Anticipated commercialization timelines
21:34 – TRYP Therapeutics’ competitive advantage
27:22 – Expected relationship with the traditional pharmaceuticals industry and potential partnerships
Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!
Pertinent links:
Tryp Therapeutics’ Mission:
https://tryptherapeutics.com/
Tryp’s pipeline progress:
https://tryptherapeutics.com/pipeline/
Follow us on social media! 🙌
Instagram: @thepsychedelicinvestor
Facebook: @thepsychedelicinvestor
Want to collaborate? Send us an email at:
thepsychedelicinvestor@gmail.com
Music from:
www.bensound.com
Video editing: @themyaholy
Check out our Benziga discounts
https://benzinga.grsm.io/jameshallifax1834
https://benzinga.grsm.io/thepsychedelicinvestor
DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.
Full Disclosure: This video is for entertainment only and shouldn’t be taken as investment advice, Pursuant to an agreement between The Psychedelic Investor and a third party. The Psychedelic Investor has been hired for a period beginning on 29,06,2021 and ending on 29,06,2021 to publicly disseminate information about (TRYP) via digital communications. We have been paid ($1000) .
https://tryptherapeutics.com/
CSE: TRYP | OTC: TRYPF
#TRYP #TrypTherapeutics #TrypStock